Biofrontera Inc. (BFRI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Biofrontera reported revenue of $41.7M, up 11.7% from $37.3M the year before. Net income was -$10.5M (a -25.3% net margin), or -$1.04 per diluted share. Operating margin was -27.2%. Operating activities generated -$13.4M of cash, leaving -$13.4M of free cash flow. At fiscal year end, Biofrontera held $28.6M in total assets against $18.1M in total liabilities, including $6.4M of cash and equivalents.
Open the full interactive Biofrontera financials → Quarterly statements, key ratios, valuation history and price charts.
Biofrontera Key Stats
| Share Price | $0.89 |
|---|---|
| Market Cap | $11.5M |
| Revenue YoY Growth | +11.8% |
| 52-Week Range | $0.57 – $1.61 |
| Shares Outstanding | 12.9 million (basic, 2026 Q2) |
Biofrontera Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Cost of Goods Sold | — | — | — | $54.5M | — |
| Gross Profit | — | — | — | -$17.2M | — |
| Operating Income | -$25.2M | -$18.6M | -$22.7M | -$17.2M | -$11.3M |
| Pre-Tax Income | -$37.7M | -$608,000 | -$20.1M | -$17.7M | -$10.5M |
| Income Tax | $56,000 | $32,000 | $14,000 | $22,000 | $25,000 |
| Net Income | -$37.7M | -$640,000 | -$20.1M | -$17.8M | -$10.5M |
| Diluted EPS | -$85.60 | — | -$13.02 | -$3.22 | -$1.04 |
Biofrontera Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.0M | $17.1M | $10.1M | $12.0M |
| Net Income | -$6.6M | $5.6M | -$4.8M | -$604,000 |
| Diluted EPS | -$0.62 | $0.55 | -$0.41 | -$0.05 |
Biofrontera Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.5M | $17.2M | $1.3M | $5.9M | $6.4M |
| Current Assets | $46.4M | $43.1M | $23.1M | $20.7M | $18.1M |
| Total Assets | $53.2M | $50.9M | $27.9M | $22.1M | $28.6M |
| Current Liabilities | $13.8M | $20.9M | $18.1M | $12.0M | $11.9M |
| Total Long-Term Debt | — | — | — | $4.1M | $4.6M |
| Total Liabilities | $41.9M | $27.0M | $23.1M | $17.7M | $18.1M |
| Shareholders' Equity | $11.3M | $23.9M | $4.8M | $4.4M | $10.5M |
Biofrontera Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Cash From Investing | -$11,000 | -$5.2M | $619,000 | -$3,000 | $3.0M |
| Cash From Financing | $43.2M | $14.0M | $8.4M | $14.8M | $10.8M |
| Free Cash Flow | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
Figures from Biofrontera's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biofrontera financials page for every line item.
Biofrontera Company Profile
| Ticker | BFRI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Woburn, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001858685 |
Frequently Asked Questions
What was Biofrontera's revenue in fiscal 2025?
Biofrontera (BFRI) reported revenue of $41.7M for fiscal 2025.
What is Biofrontera's annual revenue history?
Biofrontera's annual revenue by fiscal year: 2021: $24.1M; 2022: $28.7M; 2023: $34.1M; 2024: $37.3M; 2025: $41.7M.
What was Biofrontera's net income in fiscal 2025?
Biofrontera reported net income of -$10.5M for fiscal 2025.
What was Biofrontera's earnings per share (EPS) in fiscal 2025?
Biofrontera's diluted EPS was -$1.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biofrontera generate in fiscal 2025?
Biofrontera generated -$13.4M of free cash flow in fiscal 2025.
What was Biofrontera's revenue last quarter?
In its most recent reported quarter (2026 Q2), Biofrontera reported revenue of $12.0M.
How much debt does Biofrontera have?
Biofrontera reported $4.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biofrontera are outstanding?
Biofrontera reported a weighted average of 12.9 million basic shares outstanding in 2026 Q2.
What is Biofrontera's market cap?
Based on its latest closing price, Biofrontera (BFRI) has a market capitalization of about $11.5M.
When does Biofrontera's fiscal year end?
Biofrontera's fiscal year end, as registered with the SEC, is December 31.
Where is Biofrontera headquartered?
Biofrontera lists its business address in Woburn, Massachusetts in its SEC filings.